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In a previous double blind placebo-controlled
study (1), topical administration of several anti-
tumor agents was found to alter the natural
course of solitary basal cell carcinoma, including
complete regression in a statistically significant
number of lesions. Several studies on the effects
of local administration of chemotherapeutic
agents to tumors in the skin and subcutaneous
tissues, previously reported from this group
(2—7) and other investigators (8—12), indicated
that further investigation is warranted. This
paper reports the effects of local administration
of anti-tumor agents on multiple superficial
basal cell epitheliomas.
Comparative studies on various agents, drug
concentrations, durations of application, fre-
quencies of application, methods of dressing
and area sizes can be carried out in a single
patient with multiple epitheliomas. The cor-
responding effects of various agents and drug
concentrations upon the normal skin surround-
ing the tumors can be compared with each other
and with control sites in the same patient.
In addition to being suitable for comparative
studies of anti-tumor agents, multiple superficial
epitheliomatosis is frequently a difficult thera-
peutic problem. Local chemotherapy was there-
fore explored in patients in whom the areas of
the skin involved by tumor were large, thus
making difficult the management by surgery or
radiation. This study indicates that although the
topical administration of anti-tumor agents to
multiple epitheliomas is still an investigative
technic, it is possible that topical administration
of anti-tumor agents may become a practical
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approach to the management of multiple super-
ficial epitheliomatosis.
METHODS
The seven patients in this study are quite dis-
similar in regard to the number, distribution, and
duration of tumors. The studies carried out in
each patient were guided by the number, sizes, and
anatomic sites of the tumors. Since the patients
are dissimilar and since several agents and various
drug concentrations were to be studied, the agents
and their concentrations were varied among the
patients. The agents were applied topically as
ointments or were injected intracutaneously or
subcutaneously in aqueous solution. The vehicles
for topical application were Acid Mantle cream,
Plastibase or aquaphor. The agents were admin-
istered daily or every other day. Some areas were
covered with plastic occlusive dressing after each
topical application while the other areas were not
covered occlusively. Duration of the courses of
application varied from three days to forty-three
days. The response of the tumors was assessed
by frequent inspection, photography, and micro-
scopic examinations of serial biopsy specimens.
Duration of observation following cessation of the
applications varied from 6 months to more than
3 years.
Two groups of studies were carried out. In the
first group of studies, multiple individual lesions
were studied by administration of different agents
or different concentrations of a selected agent to
each individual lesion (Study Program I). In the
second part of the study, multiple grouped or
confluent lesions covering large portions of the
skin were submitted to a single concentration of a
single agent to an entire study area (Study Pro-
gram II).
Study Program I
Investigational
In Study Program I the anti-tumor agents were
administered by injection or inunction. The agents*
* The chemical agents were obtained as follows:
5-Fluorouracil through the cooperation of Dr. E.
Miller, Hoffman-La Roche, Inc., Nutley, N. J., 5-
Mercaptouracil and Dimethylurethimine through
the cooperation of Dr. T. Bardos, School of Phar-
macy, State University of New York at Buffalo
and Dr. J. Ambrus, Department of Experimental
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injected as aqueous solutions were: 0.5% 5-
Flourouracil (5-FU), 5.0% 5-FU, 5.0% Dimeth-
ylurethimine (AB 132), 10.0% 5-Meraptouracil
(AB 050), 0.05% Methotrexate, 0.2% Methyl-
Glyoxal-bisguanylhydrazone HC1. The agents*
administered as ointments by topical application
were: 20.0% 5-FU, 0.02% Actinomycin D, 20.0%
AB 050, 20.0% Methotrexate, 20.0% AB 132, 0.005%
Nitrogen Mustard, 5.0% 5-iodo-2-deoxyuridine
(IDUR) and 1.0% Cytosine arabinoside.
The reactions of the superficial basal cell car-
cinomas in this study were similar to those de-
scribed in the study of the local administration of
anti-tumor agents to single basal cell carcinomas
(1). All of the agents studied produced some effects
upon the tumors. The changes observed most
often were erythema, followed by erosion of a
part or all of the tumor surface. Necrosis of the
tumor, superficial ulceration and crust formation
were observed occasionally with most agents but
regularly only with 5-FU. Eczematization (vesicu-
lation and crusting) of the tumor and the skin
surrounding the tumor sometimes occurred during
the application of AB 132, AB 050, and IDUR.
As in the study of solitary basal cell epithelioma
(1), 5-FU was the only agent which regularly
produced tumor necrosis and regression. Tinder the
conditions of this study, the agents other than
5-FU did not produce predictable or consistent
tumor resolutions. Complete tumor resolution fol-
lowed the application of AB 050, methotrexate,
IDUR, and cytosine arabinoside in a small number
of instances.
Although tumor regression following metho-
trexate was not consistent, the three superficial
basal cell carcinomas which resolved after applica-
tion of methotrexate cream reacted in a manner
quite similarly to the reaction evoked by 5-FTJ:
erythema and necrosis were sharply limited to the
tumor; exfoliation of the firm adherent crust that
formed following cessation of application of metho-
trexate left a smooth pink slightly atrophic scar
(Figs. 1, 2).
Application of 5-FU cream or injection of
aqueous solution of 5-FU was followed within 24
hours by erythema in most tumors (Fig. 3). Most
tumors became raised slightly within 2 or 3 days
(Fig. 4). Following the initial swelling superficial
denudation appeared in portions of the tumor
Biology, Roswell Park Memorial Institute, Buffalo,
New York; spiramycin through the cooperation ofDr. N. Back of the School of Pharmacy, State
University of New York at Buffalo; Actinomycin
D through the cooperation of Drs. J. Scigliano and
A. Osterberg of the Cancer Chemotherapy Na-
tional Service Center, National Institutes of
Health, Bethesda, Maryland; Methotrexate
through the cooperation of Dr. J. Ruegsegger of
the Lederle Laboratories, Pearl River, N. Y.;
Nitrogen Mustard as Mustagen, Merck Sharp and
Dohme, West Point, Pa.; IDUR through the co-
operation of Dr. M. Boghosian, The Allergan Co.,
Santa Ana, Calif., and Cytosine Arabinoside
through the cooperation of Dr. L. Rhuland of the
Upjohn Co., Kalamazoo, Mich.
(Fig. 5). Necrosis of tumor was evidenced by
ulceration and, after cessation of the administra-
tion, crust formation (Fig. 6). Exfoliation of the
crust left a firm, erythematous atrophic scar (Fig.
7). Resolution of very superficial tumors left
atrophy which was so slight as to be barely dis-
cernible.
Study Program II
Because application of 5-FU resulted in tumor
regression more consistently than the other agents
under the conditions of this study and because
5-FU produced no significant local or systemic
morbidity, this agent was used in the patients
studied in the second group of studies. In the
second study program the concentrations of 5-FU,
administered by topical application, were 0.5%,
1.0%, 2.0%, 5.0%, 10.0% and 20.0%. The various
concentrations of 5-FTJ were applied daily for 10
to 43 days. Some areas were covered (daily) with
occlusive plastic bandages; some areas were not
occluded or covered. Because the epitheliomas
were numerous and either in close proximity to
each other or frankly confluent, the exact number
of tumors in each study area was impossible to
determine (Fig. 8). The number of lesions counted
in each area studied was the minimum number
present, since, as will be shown, some previously
inapparent tumors became evident during the
study. As the number of lesions studied was an
approximation, so was the number of tumors that
resolved an approximation. At the completion of
the study of each area, the number of sites that
appeared grossly to contain residual epithelioma
was estimated and representative sites were ex-
amined by biopsy. The estimates of the number
of residual tumors were probably quite accurate
because all areas even slightly suspicious for tu-
mor were counted as residual tumor and the rep-
resentative specimens confirmed the clinical im-
pressions in almost all instances.
The first patient studied was a 49 year old
female with the basal cell nevus syndrome. The
patient had a history of successive crops of skin
tumors since the age of 14. She had been treated
on numerous occasions with all the standard
modalities (radiation, excision, electrosurgery). At
the time of this study, she presented innumerable
superficial, multiple basal cell carcinomas (for
which she had refused standard therapy for the
preceding four years) and scars of previous treat-
ments on her head, trunk and extremities. Topical
administration of 5-FU cream was carried out on
several large areas including the chest, the back
and the legs. The chest was covered by almost
confluent superficial epitheiomas and scars of
previous treatments such that the number of
distinct lesions could not be counted. Cream con-
taining 1% 5-FU was applied under occlusion for
four days to the right chest and for 17 days to the
left chest. Marked erythema and denudation
appeared in the tumor areas. Six months after the
administration of 5-FU had been stopped, approxi-
mately 10% of the treated area on the right chest
LOCAL CHEMOTHERAPY IN EPITHELIOMATOSIS 491
FIG. 1. Basal cell carcinoma prior to topical application of 20% Methotrexate in hydro-
phthc base.
Fie. 2. Site of lesions shown in Fig. 1 at 6 weeks following 4 week course of daily topical
apphcation of 20% Methotrexate in hydrophihc base.
FIG. 3. Superficial basal cell carcinoma prior to study.
FIG. 4. Same area as shown in Fig. 3 after 9 days of 5-FU application. Elevation of the
tumor is evident.
. .
FIG. 5. Same area as shown in Fig. 3 after 2 weeks of 5-FIJ application. Initial swelling
with superficial denudation is evident.
FIG. 6. Same area as shown in Fig. 3 after completion of 4 weeks of 5-FU application.
Necrosis and ulceration are quite pronounced.
and 20% of the treated areas on the left chest
contained tumor.
During the courses of 5-FU application a num-
ber of areas that had not previously appeared to
be epitheliomatous became erythematous and
swollen. Biopsy examination of these sites showed
superficial basal cell epitheiomas. Thus, areas
which had no clinical evidence of neoplasm prior
to application of 5-FU, reacted and the neoplasms
became clinically apparent during the course of
applications (Figs. 9, 10). The initially obvious
lesions, as well as those which became apparent
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FIG. 7. Same area showing erythematous, atrophic scar 3½ months after completion of
treatment.
FIG. 8. Extensive involvement by confluent and closely adjacent multiple superficial basal
cell carcinoma prior to 5-FE application.
FIG. 9. Area prior to application of 5-FE with small number of lesions clinically evident.
FIG. 10. Same area during course of application of 5-FE. Reaction to 5-FU revealed
numerous epitheliomatous lesions which were too small to be clinically evident prior to 5-FE
application.
FIG. 11. 3 areas of superficial basal cell carcinoma during course of application of 5 FE
including area shown in Figs. 8, 9 and 10.
FIG. 12. Same 3 areas as shown in Fig. 11, 12 months after completion of 5-FU application.
No residual or recurrent tumors present.
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during the course of 5-FU administration, sub-
sequently underwent complete resolution (Figs. 11,
12).
The right and left legs contained numerous
discrete basal cell epitheliomas. The diameters of
the lesions varied from 2 to 5 mm except for one
large tumor, which was 1.5 cm in diameter. 5%
5-FU cream was applied without occlusion 2 or 3
times daily for 43 days to the right leg. Very
slight erythema appeared in some tumors, but
there was virtually no tumor regression. 10% 5-FE
cream was applied without occlusion 2 or 3 times
daily for 38 days to the left leg. Erythema and
swelling occurred in some tumors, but as with the
right leg, tumor resolution was not seen.
The marked response observed on the chest was
induced by 1% 5-FE cream. The very minimal
response seen on the legs was obtained with 5%
and 10% 5-FE cream, respectively. The contrast in
response and degree of tumor resolution between
the different sites studied on the chest and legs
may have been due to the different modes of ad-
ministration.
The second patient was an 86 year old female
with multiple superficial basal cell epitheliomas of
the trunk and lower extremities. The patient ob-
jected to further conventional methods of therapy.
The areas studied, the concentrations of 5-FE
in the cream, the use of occlusive dressing, the
duration of the application, the number of tumors
in each area, and the number of tumors which
resolved is outlined in Table I. These areas have
remained unchanged for eight to ten months after
cessation of 5-FE application.
The third patient was a 58 year old male with
multiple basal cell carcinomas of the trunk. Twenty
years ago, he had received multiple increments of
X-ray therapy to the face, neck, back and chest.
The epitheliomas in this patient had been pre-
viously treated by radiation, surgery and electro-
surgery.
The two areas studied were the left chest and
the right chest. Each side of the chest contained
about thirty superficial basal cell carcinomas vary-
ing from 3 to 10 mm in diameter.
A cream containing 5% 5-FE was applied to the
left side (whole area) twice daily without occlusive
dressing. The tumor became erythematous and
swollen but did not show eczematization or ulcera-
tion. The erythema and swelling were sharply
limited to the tumors. Following cessation of the
applications the erythema gradually disappeared
and the swollen tumors became progressively
flatter. Two months after stopping treatment 6
basal cell carcinomas remained clinically evident
in the study area.
To the right side of the chest 10% 5-FE cream
was applied (to the whole area) twice daily with-
out occlusive dressing. The tumors reacted with
erythema and swelling similar to those treated
with 5% 5-FE cream but the degree of erythema
and swelling was more marked. Four months after
TABLE I
Effects of varying concentrations of topically
applied 5-FU in hydrophilic base
Area
Concen-
tration
of 5-FU
Occlu-
.sire
Dress-
ing
Days of
Appli-
Cation
Number
of
Tumoss
No. of
Tumors
Re-
solved
Right upper 20% No 33 20 17
back
Left upper 10% No 33 35 25
back
Lower back 5% Yes 7 44 41
Right thigh 10% Yes 10 21 18
Left thigh 5% Yes 12 10 10
Right leg 1% Yes 11 34 31
Left leg 1% Yes 17 53 49
stopping treatment there wore four basal cell
carcinomas clinically evident in the study area.*
DISCUSSION
concentration of a single anti-tumor agent has
been shown to be feasible by simultaneous ad-
ministration to multiple tumors in one patient.
A systematic study of this type comparing four
concentrations of 5-FE cream is now being
conducted.
The observations described above have indi-
cated, furthermore, that multiple superficial
basal cell epitheliomatosis may provide a rapid,
safe and practical screening system for ex-
ploratory assessment of anti-tumor activity in
humans. In order to evaluate basal cell epithelio-
matosis as a potential screening system, further
studies are required to determine how anti-tumor
* This patient is presently still under study.
Areas on his back are being studied with the con-
centrations of 5-FE which had been used on his
chest but some areas are being dressed with oc-
clusive plastic film in order to compare the results
in areas treated with and without occlusion.
The effects of several concentrations of various
anti-tumor agents upon multiple superficial basal
cell epitheliomas were studied in the first part
of this study for general orientation. Tinder the
conditions of this study, all agents produced
some effect upon the tumors although in a
number of instances the effects were limited to
barely perceptible erythema. Several agents pro-
duced gross tumor resolution, subsequently
confirmed by biopsy examination. 5-FE pro-
duced tumor regression more consistently than
any other agent. Comparative study of various
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activity against basal cell carcinoma may be re-
lated to anti-tumor activity against other neo-
plasms. Continuing study in this direction may
reveal the manner in which a skin tumor system
may be applied to the investigation of other
aspects of tumor biology and chemotherapy in
man. These aspects would include the study of
host defences against tumors (particularly as
they undergo regression) without the depres-
sion of these defences, induced by systemic ad-
ministration of most anti-tumor agents. The
accessibility of skin tumors, furthermore, facili-
tates the study of mechanisms of anti-tumor
action by the relative ease of serial procurement
of specimens for histological, histochemical and
biochemical investigation. The introduction of
metabolites and antagonists of anti-tumor agents
is also facilitated, as are studies on turnover
rates, localization and determination of tissue
levels of anti-tumor agents. Such studies may
provide information on the requirements which
permit eradication of skin tumors by chemical
agents. This information may be of relevance
to the chemotherapy of deep seated tumors.
While local chemotherapy in multiple discrete
epitheliomas may be of value as an easily ac-
cessible system for studying anti-tumor drug
activity, it may also provide an approach to the
problem of removing large confluent areas of
multiple basal cell epitheliomatosis, which pre-
sent difficulties in clinical management by stand-
ard methods. The observations made in the
second study program suggest that the topical
application of 5-FT5 cream appears to justify
further investigation in this regard. Although
complete resolution of all epitheliomas did not
occur in a number of study sites, the eradication
of tumor in a large proportion of the involved
area was of very considerable practical signifi-
cance. Several months following cessation of
application of 5-FU, small, discrete areas of
residual epithelioma were easily amenable to
excision, electrocoagulation or further local
chemotherapy. Areas of epitheliomatosis as large
as one half of the chest or back present virtu-
ally insurmountable problems in treatment when
the tumor involvement is so confluent that no
clearly definable margins are evident. Electro-
coagulation and radiation are impractical be-
cause of the extensive field sizes. Although
plastic surgery may present a possible approach
to the removal of such large areas of tumor,
provided large flaps can be successfully devised
to resurface the excision areas, the problem of
multicentricity of epitheliomatosis remains. The
skin used to form flaps often itself develops
multiple epitheliomas.
Several unknown factors must be evaluated
before the possible clinical application of topical
chemotherapy can be determined. Although large
areas of epitheliomatosis have been followed up
to 12 months after treatment, longer follow-up
periods will provide a more meaningful estimate
of the tumor regression rate. Furthermore, the
optimum concentration of 5-FU for treating
large areas has not been determined. The ob-
servations made in these studies suggest that
the minimum effective dose may vary with the
anatomical sites and with different patients.
Such factors as frequency of administration
and duration of course of administration have
not been evaluated. Whether or not the large
areas should be covered with occlusive film has
not been definitively decided, although the ob-
servations in this study suggest that occlusion
enhances the anti-tumor effect. Availability of
5-FIT to the tumor may well vary with different
ointment bases; a study is now being conducted
to compare a number of ointment bases in re-
gard to the efficacy of topical 5-FIT administra-.
tion. These and other clinical considerations
indicate that considerable additional studies are
warranted. This preliminary study, however,
suggests that large areas of superficial basal cell
epitheliomatosis can be favorably affected by
topically applied 5-FTJ.
Previous studies had indicated that topical
administration of 5-FIT had minimal toxic effects
on the normal skin and subcutaneous tissues
adjacent to the tumor, while it induced necrosis
in the neoplastic tissues at the same time. Lack
of significant effects was also observed in normal
skin at control sites. It therefore, did not appear
necessary, nor was it feasible, to limit topical
administration of 5-FIT to tumor sites when
large areas of the skin were involved by (nearly)
confluent or closely adjacent basal cell carci-
nomas. Under these conditions, again, minimal
adverse effects of 5-FIT on the normal skin,
intervening between or adjacent to the tumors,
was observed, indicating differential effects on
normal and neoplastic tissues respectively.
Diminutive lesions of basal cell carcinoma,
however, became recognizable by their reaction
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to topically applied 5-FU, although they had
previously not been detectable by clinical exami-
nation. This may be of value for the early recog-
nition and eradication of tumors, particularly in
patients with multiple concurrent and frequently
arising new crops of basal cell carcinomas.
Parallel investigations on solar and arsenical
keratoses, on carcinoma in situ and on metastatic
tumors in the skin indicate that these types of
lesions are suitable for studies analogous to
those reported here on basal cell carcinomas.
These considerations suggest that additional
studies of the effects of locally applied anti-tumor
agents are warranted.
SUMMARY
The topical application and intralesional in-
jection of several anti-tumor agents were ac-
companied by changes in the natural course of
multiple basal cell carcinomas. Under the condi-
tions of these studies 5-Fluorouracil produced
tumor resolution more consistently than other
anti-tumor agents. Topical application of 5-FU
cream to large areas of confluent or closely ad-
jacent multiple superficial basal cell epitheiomas
resulted in tumor regression over large propor-
tions of the involved areas. Minimal effects on
normal skin adjacent to tumors were observed.
Small lesions of basal cell carcinoma became
recognizable by their reaction to topical 5-FU
at a stage at which they were not otherwise
clinically detectable. In view of the limited in-
formation available at present, local chemother-
apy is an investigative procedure, and not
indicated for the routine clinical management
of skin cancer.
Further investigation of the effects of local
administration of anti-tumor agents to cutaneous
neoplasms are warranted in regard to studies
on human tumor biology and mechanisms of
chemical anti-tumor action, for screening of
anti-tumor agents, and as a possible approach
to the management of cutaneous tumors involv-
ing large areas of the skin.
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DISCUSSION
Dn. ROBERT AUERBACH, New York, N. Y.: I
would like to suggest that in addition to therapy,
which still remains to be developed, chemothera-
peutic agents may be useful in delineating which
areas of previously treated ulcers still contain
the basal cell. In the occasional problem case
where there is a large recurrent ulcerated basal
cell it is sometimes difficult to know which edge
is just not healing, which edge is infection and
which is tumor. I think this is demonstrated in
the patient with small superficial basal cell
epitheliomas which were detected after the drug
was put on. When Dr. Van Scott used intrave-
nous methotrexate in the treatment of basal
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cell epitheliomas, while it was not too effective
in therapy, it served as a very efficient marker
for the areas of the basal cell tumor.
Da. EUGENE J. VAN SCOTT, Bethesda, Md.: It
seems quite probable that topically applied
5-Fluorouracil may be effective on superficial
basal cell tumors because of increased permea-
bility of the epidermis overlying such tumors.
Possibly other agents, found to be ineffective, are
ineffective because of their inefficient permeabil-
ity through the epidermis. Could I ask the
presenter's thoughts on this?
DR. WALTER F. LEVER, Boston, Mass.: I
would like to ask Dr. Klein two questions in re-
gard to his interesting presentation. In the
first place, which method do you prefer, the
open application or the occlusive application;
and, if you use both methods, for which pur-
pose do you use the one method and for which
purpose the other? And, secondly, do you let
the patient apply the preparation himself? You
stated that the antimitotic agents were applied
daily for a month or longer; do you regard it as
safe for the patient to do it himself?
DR. ALFRED W. KOI'F, New York, N. Y.: A
word of caution should be expressed in the
use of topically applied chemotherapeutic agents
in the destruction of cutaneous carcinomas. This
approach in its present stage should be consid-
ered a research tool which has not had sufficient
clinical trial and follow-up to warrant suggesting
it for general use. Furthermore, 5-Fluorouracil
is not commercially available for this purpose.
We have treated a small series of patients with
histologically proven basal cell epitheliomas with
0.5% colchicine in Hydrophiic Ointment (USP)
applied twice daily beneath Telfa gauze with
some success. However, several lesions, even
after four months of such treatment, failed to
respond as indicated by persistence of tumor
cells histologically.
I would like to ask Doctor Klein if he or his
colleagues have encountered any complications
such as delayed tumor response in their series.
DR. EDMUND KLEIN (in closing): Local chem-
otherapy is an investigative and not a routine
clinical procedure at this stage of our studies.
The main purpose was to explore it as an ap-
proach to the study of those aspects of tumor
biology and chemotherapy which cannot be
readily investigated by systemic administration
of chemotherapeutic agents. The complications
that were mentioned by Dr. Kopf in regard to
topical coichemide derivatives are very real.
With 5 FTJ we have not encountered submerged
islands of tumor cells with apparent clinical
cure, but with other agents we have had that
experience. This phenomenon was described
three or four years ago by Dr. Sullivan and
co-workers. They had observed rather protracted
disappearance of cutaneous tumors following
local administration of podophyllin derivatives.
An appreciable number of tumors, however, re-
curred. Recurrence was not necessarily accom-
panied by gross indications of the presence of
tumor and might not have been recognized with-
out repeated biopsy examinations. I think it
should be clearly understood that 3 years is not
an adequate observation period for definitive
evaluations of a new approach to the control of
cutaneous neoplasms.
In regard to Dr. Auerbach's statement, we be-
lieve that it might be feasible to use topical
agents as markers for tumors. In this connection
it is of interest, as Dr. Auerbach mentioned,
that systemic administration of MTX "marked"
the location of tumor involvement in patients
with multiple superficial basal cell carcinomas
by producing a differential inflammatory reac-
tion at the tumor sites. This would indicate
that this "marking" phenomenon is induced by
the antitumor agent regardless of the route of
administration. The differential interaction be-
tween anti-tumor agents and the tumor site,
therefore, is not due entirely to preferential
absorption of topically applied anti-tumor agents
through the tumor surface, but appears to be
related to a more general property.
We have had no reason to be concerned about
superimposed infection, because most of the
anti-tumor agents used in our studies inhibit
bacterial growth; i.e., the cultures that we have
taken, were sterile. There are of course micro-
organisms which will not be inhibited by these
agents.
As Dr. Van Scott pointed out, absorption
through the tumor surface or skin is a pre-
requisite. For that reason MTX which is poorly
absorbed, will not show much anti-tumor action
on topical administration. We discontinued the
exploration of methotrexate as a topical anti-
tumor agent except for selected studies, because
our results were not impressive, as Dr. Van
Scott reported several years ago.
As far as the inhibition of epidermal growth
by 5 FU is concerned, I would assume that any
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regenerating tissue would incorporate 5 FIJ and
would therefore be inhibited in this process.
We have noticed some protracted inhibition of
re-epithelialization in one patient. It was several
months before epithelialization was complete.
This delay in epithelialization, as well as obser-
vations on delayed regression of tumors, at some
time after 5 FTJ administration had been dis-
continued, raises interesting questions of 5 FU
transfer and economy during DNA production.
As far as Dr. Lever's question is concerned,
we are in the process of evaluating occlusion
versus non-occlusion as a mode of administra-
tion. I think from a practical point of view, our
decision will likely depend on the area involved.
If the area can be easily occluded, I feel almost
sure that it will be preferable to do so, depending
again on the conditions of the study which is
being undertaken. If the area cannot be easily
occluded, for instance the entire back, I would
assume that it would be preferable to explore
higher concentrations of the antitumor agent
without occlusion.
I should mention in this connection that we
are investigating agents which may alter the
permeability characteristics of the barrier,
keratolytic agents, agents of the adamantine
series, and of the DMSO and dimethylacetamide
series in the hope of detecting, by radioactively
labeled compounds, the rate of absorption, turn-
over, retention and release in the areas to which
the agent is applied.
